- Open Access
Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors
© Molatore et al; licensee BioMed Central Ltd. 2010
- Received: 18 December 2009
- Accepted: 21 May 2010
- Published: 21 May 2010
p27Kip1 (p27) is an important negative regulator of the cell cycle and a putative tumor suppressor. The finding that a spontaneous germline frameshift mutation in Cdkn1b (encoding p27) causes the MENX multiple endocrine neoplasia syndrome in the rat provided the first evidence that Cdkn1b is a tumor susceptibility gene for endocrine tumors. Noteworthy, germline p27 mutations were also identified in human patients presenting with endocrine tumors. At present, it is not clear which features of p27 are crucial for this tissue-specific tumor predisposition in both rats and humans. It was shown that the MENX-associated Cdkn1b mutation causes reduced expression of the encoded protein, but the molecular mechanisms are unknown. To better understand the role of p27 in tumor predisposition and to characterize the MENX animal model at the molecular level, a prerequisite for future preclinical studies, we set out to assess the functional properties of the MENX-associated p27 mutant protein (named p27fs177) in vitro and in vivo.
In vitro, p27fs177 retains some properties of the wild-type p27 (p27wt) protein: it localizes to the nucleus; it interacts with cyclin-dependent kinases and, to lower extent, with cyclins. In contrast to p27wt, p27fs177 is highly unstable and rapidly degraded in every phase of the cell-cycle, including quiescence. It is in part degraded by Skp2-dependent proteasomal proteolysis, similarly to p27wt. Photobleaching studies showed reduced motility of p27fs177 in the nucleus compared to p27wt, suggesting that in this compartment p27fs177 is part of a multi-protein complex, likely together with the degradation machinery. Studies of primary rat newborn fibroblasts (RNF) established from normal and MENX-affected littermates confirmed the rapid degradation of p27fs177 in vivo which can be rescued by Bortezomib (proteasome inhibitor drug). Overexpression of the negative regulators microRNA-221/222 plays no role in regulating the amount of p27fs177 in RNFs and rat tissues.
Our findings show that reduced p27 levels, not newly acquired properties, trigger tumor formation in rats, similarly to what has been observed in mice. The molecular characteristics of p27fs177 establish MENX as a useful preclinical model to evaluate compounds that inhibit p27 degradation for their efficacy against endocrine tumors.
- MCF7 Cell
- Neuroendocrine Tumor
- Fluorescence Recovery After Photobleaching
- Fluorescence Recovery After Photobleaching Recovery
The putative tumor suppressor p27Kip1 (referred to as p27) controls the progression from G1 to the S phase by regulating the activity of cyclinE/and cyclinA/Cdk2 complexes . Several external signals regulate the intracellular level of p27 by either causing its increase (i.e. serum deprivation, TGFβ, contact inhibition) or its decrease (serum stimulation, estrogen, PDGF and others), thereby rendering p27 a central mediator of mitogenic and anti-mitogenic signals . In addition to its negative role in cell cycle progression, p27 is involved in cell migration, neuronal differentiation and apoptosis [3–5]. Through studies of a mouse strain expressing a p27 protein impaired in cyclin/Cdk binding it has been demonstrated that p27 has a pro-oncogenic effect when it cannot bind to cyclin/Cdk complexes .
The intracellular level of p27 is regulated at the transcriptional, translational and post-translational level [7, 8], but the best known mechanism is ubiquitin-mediated proteasomal degradation. Two main pathways involved in p27 degradation have been identified. The first is mediated by the Skp2-dependent SCF (skp-cullin-f-box) E3 ligase: phosphorylation of p27 by cyclinE/Cdk2 at a conserved threonine (Thr187) creates a binding site for Skp2, which allows polyubiquitylation and subsequent proteasomal degradation of p27. This degradation pathway is active in the nucleus of G1-S and G2 phase cells [3–5, 9]. The second pathway is mediated by the KPC ubiquitin ligase and is responsible for the degradation of p27 in the cytoplasm at the G0-G1 transition .
Phosphorylation at specific residues regulates the activity of p27: phosphorylation at serine (Ser) 10 regulates its subcellular localization and stability [11, 12]. Studies of p27S10A (serine 10 substituted by alanin) knock-in mice demonstrated that phosphorylation at Ser10 stabilizes p27 during quiescence by affecting its ability to bind to cyclin-CDK complexes . Ser10 phosphorylation also triggers the export of p27 from the cell nucleus to the cytoplasm upon mitogenic stimuli, thereby allowing the protein's degradation by the KPC ubiquitin ligase . Phosphorylation of p27wt at Thr187, as mentioned above, targets p27 for proteasomal-mediated degradation , while phosphorylation at Thr198 prevents ubiquitin-dependent degradation of free p27 and regulates the stability of p27 in G0 phase .
We recently identified a Cdkn1b germline frameshift mutation as the cause of a recessive multiple endocrine neoplasia (MEN)-like syndrome (named MENX) in the rat . Rats affected by this syndrome (homozygous mutants) share phenotypic features with the p27 -/- knock-out mice (increase in size, pituitary tumors) but show additional neuroendocrine tumors (adrenals, thyroid, parathyroid). Interestingly, we and others identified CDKN1B germline mutations in patients with a MEN type 1 (MEN1)-like features, thereby establishing a direct link between p27 alterations and tumor predisposition also in humans (MEN4; OMIM # 610755) [17–19]. Germline CDKN1B mutations are a rare event in patients with an MEN1-like phenotype (estimated to be around 1.5-2.8% of cases) [18, 19], and some studies failed to identify them [20, 21]. So far, five germline CDKN1B mutations have been reported and the in vitro functional studies performed on three of them show that these alterations affect the ability of the encoded protein to bind its usual protein partners (p27P95S variant) or affect its amount (ATG-7G>C; stop->Q) . Interestingly, the phenotype of the stop->Q germline mutation can be rescued by proteasomal inhibition in vitro .
In the MENX model, p27 protein expression is reduced or absent in the normal tissues of the mutant rats, but it becomes detectable in some advanced neoplastic lesions . Therefore, this mutation is not equivalent to a null allele and it may possess specific biological functions within this model system. The mechanisms causing reduced p27 expression in the MENX-affected rats are currently unknown.
In humans, neuroendocrine tumors are uncommon neoplasms and therefore comprehensive molecular studies are difficult to perform and clinical trials are challenging to set up. In addition, there are few suitable animal models of neuroendocrine tumors and this has hampered the development and preclinical testing of novel targeted therapeutic approaches against these tumors. In this scenario, the MENX model may be of relevance to identify novel molecular mechanisms in neuroendocrine tumorigenesis and to perform preclinical therapy-response studies. An in depth knowledge of the functional consequences of the underlying genetic mutation in Cdkn1b is a prerequisite to further exploit the MENX animal model in preclinical studies. Moreover, since germline CDKN1B mutations have been found in patients, studies of the molecular phenotype of the rat mutation may broaden our understanding of the role of p27 in tumor predisposition in humans as well. Therefore, we set out to characterize the MENX-associated p27 mutant protein in vitro and in the patients tissues. Our studies extend to the rats the observation that the amount of functional p27 is crucial for promoting neuroendocrine tumorigenesis, event that so far had been formally proven only in genetically engineered mice.
The MENX mutation in Cdkn1b affects p27 stability
Upon transfection, all fusion proteins were expressed and their size was consistent with the predicted protein length (Figure 1a). p27fs177 was expressed at much lower level then either p27wt or p27G177X. A time-course experiment showed that there is no time-dependent accumulation of p27fs177 (Figure 1b). Using immunofluorescence staining, we previously showed that a Myc-tagged p27fs177 seems to localize to the nucleus upon transfection of Rat2 cells, which express endogenous p27wt, . To avoid misinterpretation of the results due to possible interference of the endogenous p27 protein, we set out to assess the localization of p27fs177 in exponentially growing or serum-starved p27 knockout mouse embryonal fibroblasts (MEFs). Twenty-four hours after transfection the proteins are located mainly in the nucleus, regardless of whether the MEF cells are proliferating or growth-arrested (see Additional File 1).
We then tested whether the MENX mutation affects p27 steady-state abundance by changing its rate of degradation. The rate of p27 turnover was measured in exponentially growing MCF7 cells using cycloheximide (CHX) to block new protein synthesis. The endogenous p27 protein served as control for the treatment's efficacy. p27wt and p27G177× showed no decrease during this time course (0 h to 8 h), whereas p27fs177 was barely detectable already 2 hr after treatment (Figure 1c). The fast kinetic of degradation of p27fs177 was confirmed by shorter incubation with CHX (Figure 1d). Longer CHX treatments confirmed the higher stability of p27wt and p27G177× (half-life of ca. 10 hr) (data not shown). Live cell imaging of MCF7 cells transfected with p27wt or p27fs177, and treated with CHX 24 hr post-transfection, confirmed the very fast degradation of the mutant p27 protein (Figure 1e). Throughout this time frame (from 15 min up to 2 hr) p27fs177-associated fluorescence was detected only in the nucleus, suggesting that the protein is degraded in this compartment.
The truncated p27G177× protein is as stable as p27wt, suggesting that the p27-unrelated C-terminal domain of p27fs177 must be responsible for its fast degradation. To verify this hypothesis, we cloned the tail of p27fs177, in frame, at the C-terminus of a different protein, namely CDK2, to generate the CDK2-p27tail cDNA (Figure 2c and Additional File 2). We then transfected constructs expressing the wild-type CDK2 or the CDK2-p27tail cDNAs into MCF7 cells and observed that while exogenous CDK2 is expressed at high level, the CDK2-p27tail protein cannot be detected by western blotting (Figure 2c). Following immunoprecipitation, we can detect by western blotting a faint band having a size consistent with the predicted CDK2-p27tail protein length (Figure 2c). The lower expression of the CDK2-p27tail protein is not due to a lower transfection efficiency of the DNA construct, as demonstrated by co-transfection experiments with a GFP-encoding plasmid (see Additional File 3). Thus, our results suggest that p27fs177 is degraded very rapidly due to the p27-unrelated C-terminal domain. Interestingly, this domain, when located at the C-terminus, promotes the rapid degradation of an independent protein (i.e. CDK2).
Turnover of the p27fs177 protein is independent of the cell cycle phase
It has been shown that the stability of p27 is dependent on the cell cycle phase . To verify whether this applies to p27fs177 we determined the rate of its turnover in G1-phase and S-phase Clone 9 cells stably-expressing p27fs177 (Figure 2a). As p27fs177 was undetectable upon serum deprivation (G0-phase), these results were not included. The kinetic of degradation of p27fs177 is similar in both G1 and S phases of the cell cycle (Figure 2d). Similar results were also observed for p27fs177-Clone 14 (not shown).
Proteasome-mediated degradation of p27fs177 in vitro
p27fs177 is rapidly degraded in every phase of the cell cycle. p27wt is normally degraded through ubiquitin-dependent proteasomal degradation. To verify whether the proteasome mediates p27fs177 degradation, stably transfected p27fs177-Clone 9 cells were incubated with CHX in the presence or absence of the proteasome inhibitor Epoxomycin (EPOX). Epoxomycin partially inhibits the degradation of p27fs177, although the protein level is not completely restored back to that of untreated cells (Figure 2e). Similar results were obtained using a chemically distinct proteasome inhibitor, MG132 (not shown).
If polyubiquitination is a pre-requisite for proteosomal turnover, then inhibition of the ubiquitination pathway should stabilize p27fs177. We tested this hypothesis using a ubiquitin mutant (UbR7) that inhibits ubiquitin chain elongation, allowing only monoubiquitination . Cotransfection of this mutant ubiquitin increased the steady-state abundance of p27wt (control) but not that of p27fs177 (Figure 3d). This data suggests that polyubiquitination is required for p27wt but not for p27fs177 degradation, although we cannot rule out the possibility that these proteins are differentially sensitive to conjugation with UbR7.
In summary, the degradation of p27fs177 is, at least in part, mediated by the ubiquitin ligase Skp2. However, the relative differences between p27wt and p27fs177 protein levels remained under conditions of Skp2 knock-down, indicating that p27fs177 is degraded also by Skp2-independent mechanisms. We speculate that p27fs177 is directly degraded by the proteasome due to its altered conformation.
The p27fs177 protein is not phosphorylated on Ser10 but retains the ability to interact with Cdk2 and Cdk4
Studies of p27S10A knock-in mice (where Ser10 is substituted by alanine) demonstrated that phosphorylation of p27 on Ser10 normally stabilizes the protein in quiescence by decreasing its ability to bind to cyclin-CDK complexes . As p27fs177 is very unstable in G0, we asked whether this was due to lack of phosphorylation on Ser10. Hela cells were transfected with the p27wt and p27fs177, and with the control p27S10A mutant that cannot be phosphorylated at this residue. While p27wt can be detected using the anti-phospho-Ser10 antibody, both p27S10A and p27fs177 cannot be (see Additional File 5a). As p27fs177 is expressed at low level upon transfection, we also performed immunoprecipitation with the anti-phospho-Ser10 antibody to increase the sensitivity of the method. We observed that only p27wt can bind the phospho-specific antibody (see Additional File 5a). Therefore, p27fs177 is not phosphorylated at Ser10 or the proportion that is phosphorylated is below detection. Thus, lack of (or extremely reduced) phosphorylation at Ser10 may concur in making the p27fs177 protein unstable.
It has been shown that the formation of heterotrimeric p27-cyclin-Cdk complexes is required for p27 degradation as mutations that abolish the association with cyclin-Cdks stabilize p27 . Thus, we next decided to determine whether p27fs177 retains the ability to interact with Cyclin-Cdk complexes. Serum-starved and exponentially growing p27fs177-Clone 9 cells were used for co-immunoprecipitation (IP) studies. The binding of p27fs177 to Cyclin D1, Cyclin E, Cdk2 and Cdk4 was determined by western blotting. The results show that p27fs177 retains the ability to interact with all proteins albeit with different efficiencies (see Additional File 5b). Due to the low level of p27fs177 present in the cells, the amount of the Cdks bound to is accordingly low. p27fs177 binds more efficiently to Cdk4 then to Cdk2.
Nuclear dynamic of p27fs177 revealed by photobleaching
Diffusion coefficient of the various GFP-p27 fusion proteins in the nucleus.
sd (yEr ±)
Starting at 24 hr after transfection of p27fs177 in the various recipient cell lines used, the protein is localized in the nucleus (Additional File 1). At 18-20 hr a percentage of cells (ca. 30%) still show some cytoplasmic p27fs177 that has not yet been imported into the nucleus. To determine whether also in this compartment p27fs177 shows reduced molecular dynamics, we performed FRAP to measure the diffusion coefficient of the various p27 proteins in the cytoplasm at 18 hr post-transfection of Rat2 cells. The results show that in this compartment the motility of p27wt, p27fs177 and p27G177× is similar, indicating that p27fs177 is not associated to a protein complex in the cytoplasm (Additional File 6).
Instability of p27fs177 in primary rat cells
In proliferating RNFs, p27fs177 is degraded within minutes following treatment with CHX, and if we add Epoxomycin (EPOX) p27fs177 is stabilized (Figure 4b and 4c). Therefore, the low level of endogenous p27fs177 protein in RNFs is caused by its rapid degradation mediated, at least in part, by the proteasome, as seen in vitro. The mutant p27 protein is even less stable in this more physiological system than in vitro.
In REFmut cells a band migrating slower then p27fs177 can be observed at long exposure times but since it is not affected by any treatment we performed (Figure 4c) nor is the product of abnormally-spliced Cdkn1b transcripts (data not shown) we consider it p27-unrelated.
In many cell types there is an inverse correlation between p27 level and cell proliferation. To determine whether the low expression level of p27fs177 has an effect on cell cycle progression, RNFs were growth-arrested and monitored following serum stimulation over a 72-h period for cell cycle progression by flow cytometry. No significant difference in cell cycle distribution was observed by FACS analyses between RNFwt and RNFmut (Figure 4a). Thus, lack of functional p27 within the MENX model does not grossly affect cell cycle progression. This is in agreement with what has been observed in the normal tissues of MENX rats following immunohistochemical staining with the proliferation antigen Ki67 (Pellegata NS, unpublished observation).
The reduced level of p27fs177 in RNFmut is only in part explained by proteasome-mediated degradation, as it is slightly lower than that of p27wt in RNFwt cells also in presence of Epoxomycin. Recently, it has been reported that miRNA-221&222 down-regulate p27 at the post-transcriptional level in cell lines and in primary tumors [8, 25]. Therefore, we checked whether the low amount of p27fs177 in MENX-affected rat tissues and cells might also be due to an up-regulation of miRNA-221&222. Analysis of the expression of miRNA-221&222 in RNFwt and RNFmut cells, as well as in a series of normal and tumor rat adrenal tissues (organ affected by the MENX syndrome), showed no significant difference in the expression of these two miRNAs between samples expressing wild-type or mutant Cdkn1b (see Additional File 7). Therefore, a higher expression of miRNA-221&222 does not play a role in the low level of expression of p27fs177 in either rat primary cells or rat tissues.
We show here that the mutant p27 protein associated with MENX is very unstable due to the p27-unrelated C-terminal domain. Its rapid degradation is, at least in part, mediated by the Skp2-dependent ubiquitination pathway, just as p27wt. Interestingly, it has been reported that Skp2-dependent ubiquitination and subsequent degradation of p27 requires the phosphorylation of Thr187, which is then recognized and bound by the Skp2 ubiquitin ligase. Since p27fs177 lacks the Thr187 residue but its degradation is still regulated by Skp2 (as seen in siRNA knock-down experiments), we have to postulate that a Skp2-dependent but Thr187-independent mechanism for p27 degradation exists, as it had been previously hypothesized based on studies of cells (fibroblasts, thymocytes) from p27T187A (Thr substituted by Ala) knock-in mice . A mutant ubiquitin that inhibits ubiquitin chain elongation has no effect on the degradation of p27fs177, while it rescues wild-type p27 degradation, indicating that p27fs177 is also degraded by mechanisms different from those modulating the level of p27wt. However, what is relevant is that the expression of p27fs177 can be recovered by proteasome-inhibition. This finding, combined with the fact that p27fs177 retains the capacity to interact with cyclins and Cdks, suggests that if the expression of this protein can be rescued inhibiting the proteasome, it might resume its anti-proliferative activity.
The fact that p27fs177 retains the potential to bind to the usual partners of p27 is highly relevant: if this protein can be re-expressed in the tumor cells, it might then resume its inhibitory effect on the cell cycle and therefore prevent or reverse tumor growth in vivo.
Our observation that in some areas of very advanced tumors in MENX mutant rats p27fs177 is expressed at a detectable level might not be in contradiction to this hypothesis. In fact, re-expression of the protein is observed in rats whose general health status is irreversibly compromised by the detrimental effects related to tumor progression.
The slower nuclear dynamic of p27fs177 is therefore due to its being part of a multi-protein complex, likely together with the degradation machinery. This is in agreement with the finding that the nuclear Skp2 ubiquitin ligase plays a role in p27fs177 degradation.
p27 is frequently down-regulated in human tumors and in some of them increased proteasomal degradation has been identified as the cause of the reduced p27 level [27, 28]. Because of these findings, efforts have been made to identify compounds that interfere with the protein turnover machinery in order to achieve p27 re-expression in cancer cells. An example is the novel compound, Argyrin A, which specifically prevents p27 degradation and holds great promise as anti-cancer drug . Due to the characteristics of p27fs177 here described, MENX rats represent a useful pre-clinical model in which to test the efficacy of targeted therapeutic approaches aiming at inhibiting p27 degradation. Interestingly, an established anticancer proteasome inhibitor compound, Bortezomib, can rescue p27fs177 expression in fibroblasts of MENX-affected rats. Therefore, MENX might be also employed to test in vivo the efficacy of Bortezomib against neuroendocrine tumors and to study whether the potential effect of the drug is mediated by reexpression of p27 function. A Phase II clinical trial aiming at evaluating the effect of the proteasome inhibitor Bortezomib on metastatic neuroendocrine tumors failed to show any objective tumor response in this patient cohort . However, the patients had not been stratified for p27 expression, measurement of the increase in p27 expression following treatment was not among the biological end points of the study and Bortezomib induces a wide range of off-target effects . Thus, the efficacy of p27 re-expression in the treatement of neuroendocrine tumors is still an open question that can be addressed by studying MENX-affected rats.
Our findings suggest that the p27fs177 mutant protein does not acquire novel molecular properties, and triggers tumor formation in the spontaneous rat MENX model because it behaves as a hypoactive allele. So far, this had only been formally proven in various p27 knock-out and knock-in mouse models [31–33].
The identification of the molecular phenotype of the few naturally-occurring p27 mutations so far identified in MENX and in human patients is important to better understand the link between p27 and neuroendocrine tumor predisposition (and tumorigenesis in general), and may provide clues for a targeted management of the families carrying such mutations.
Plasmid constructs and antibodies
The rat wild-type Cdkn1b cDNA was cloned in the pEGFP-C3 vector (BD Biosciences, Erembodegem, Belgium) in frame with the green fluorescent protein (GFP) tag. A rat Cdkn1b cDNA containing the MENX rat mutation (p27fs177) and a rat Cdkn1b cDNA containing a stop codon at position 177 (p27G177X) were generated by PCR.
The rat wild-type Cdkn1b cDNA was cloned in the pEGFP-C3 vector (BD Biosciences, Erembodegem, Belgium) in frame with the green fluorescent protein (GFP) tag. A rat Cdkn1b cDNA containing the MENX rat mutation (p27fs177) and a rat Cdkn1b cDNA containing a stop codon at position 177 (p27G177X) were generated by PCR.
The pUbr7 construct was gently provided by N. Malek
Primary antibodies used were: anti-p27 monoclonal antibody (BD Biosciences); anti-Skp2 monoclonal antibody; anti-Cyclin A polyconal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). To control for equal protein loading, α-tubulin immunostaining (Santa Cruz) was performed.
Cell culture, transfections, protein extraction and Western blotting
MCF7 (human breast cancer) cell line was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 20 mM L-glutamine, 100 units/ml of penicillin G sodium, and 100 μg/ml streptomycin. When establishing stable transfectants, cells were selected by adding 0.4 mg/ml G418 to the culture medium.
Primary rat fibroblast cells were obtained from the epidermis of newborn rats having a p27 wt/wt (RNF wt) or a p27fs177/p27fs177 genotype (RNF mut) and were maintained in DMEM medium supplemented with 10% fetal bovine serum, 20 mM L-glutamine, 100 units/ml of penicillin G sodium, 100 μg/ml streptomycin, and Fungizone® antimycotic (Invitrogen, Darmstadt, Germany).
The cells were grown in a humidified atmosphere containing 5% CO2 at 37°C.Cells were growth arrested by decreasing the serum concentration in the medium to 0.1% for 72 h and then released by serum addition,
Asynchronously growing cells were transiently transfected with the different constructs when 70-80% confluent using the FuGene HD reagent (Roche Applied Bioscience, Basel, Switzerland). Cells were collected and lysed 24 h later in protein lysis buffer (10 mmol/l Tris-HCl pH 7·4, 5 mmol/l EDTA, 130 mmol/l NaCl, 1% Triton, and 1× Mini-Complete protease inhibitors cocktail, Roche).
Equal protein amounts (50 μg) were resolved on 4-15% SDS-PAGE pre-cast gels (Invitrogen, Darmstadt, Germany).
Drug treatments and RNA interference
The cells were treated with 25 μg/mL cycloheximide (Sigma-Aldrich Biochemie, Hamburg, Germany), 10 μM epoxomycin (Enzo Life Sciences, Lörrach, Germany), or 10 nM Bortezomib (LC Labs, Woburn, MA, USA).
For RNAi studies, short interfering RNA (siRNA) duplexes specific for Skp2 (n = 4) (1 μg; siGenome SMARTpool, Dharmacon, Lafayette, CO, USA) and KPC1 (1 μg each; ID 133486, 133487 Ambion-Applied Biosystems, Darmstadt, Germany) were obtained and transfected into MCF7 cells using X-tremeGENE reagent (Roche) together with expression plasmids for p27wt (30 ng) or p27fs177 (50 ng). To verify the specificity of the siRNA-mediated knock-down, a scrambled siRNA oligo was transfected in parallel.
MCF7 cells were plated on dishes having a cover slip for microscopy (MatTek Corporation, Ashland, MA, USA) and transfected as above with p27fs177 and p27wt protein constructs. To re-create a more physiological condition (37°C and 5% CO2), dishes were put under a micro-incubation chamber (Zeiss, Jena, Germany) mounted on a confocal laser scanning microscope (Zeiss). Images were taken every 15 min using always the same settings.
Fluorescence activated cell sorting (FACS)
Cells were collected and fixed in 70% ice-cold ethanol and stored at -20°C until ready to proceed. Cells were rinsed and resuspended in 1× PBS containing 5 μg/ml propidium iodide and 150 μg/ml RNaseA. After incubation for 30 min at 37°C cells were analyzed in a FACS machine (Beckman Coulter, Krefeld, Germany) for DNA content.
500 μg of total protein extracted from the cells were incubated with a polyclonal anti-GFP antibody (BD Biosciences) in IP buffer (5 mM EDTA, 0.5% Triton X-100 in PBS 1×) and 20 μl of agarose resin overnight at 4°C. Unbound protein fraction was removed, the resin was washed five times with IP buffer and immunoprecipitated proteins were eluted from the agarose resin using Laemmli buffer and analyzed by Western blot.
Additional experimental procedures and associated reference are available in Additional File 8.
We thank Prof. N. Malek (Hannover Medical School, Hannover, Germany) for providing the Ubr7 construct. This work was supported in part by Award #107973 from the Deutsche Krebshilfe (NSP) and by a Fellowship from Centro per la Comunicazione e la Ricerca, Collegio Ghislieri, Pavia, Italy (SM).
- Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1502. 10.1101/gad.13.12.1501View ArticlePubMedGoogle Scholar
- Philipp-Staheli J, Payne SR, Kemp CJ: p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res. 2001, 264: 148-168. 10.1006/excr.2000.5143View ArticlePubMedGoogle Scholar
- Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11: 1464-1478. 10.1101/gad.11.11.1464View ArticlePubMedGoogle Scholar
- Vlach J, Hennecke S, Amati B: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16: 5334-5344. 10.1093/emboj/16.17.5334PubMed CentralView ArticlePubMedGoogle Scholar
- Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999, 1: 193-199. 10.1038/12013View ArticlePubMedGoogle Scholar
- Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM: Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 2007, 21: 1731-1746. 10.1101/gad.1556607PubMed CentralView ArticlePubMedGoogle Scholar
- Vervoorts J, Lüscher B: Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci. 2008, 65: 3255-3264. 10.1007/s00018-008-8296-7View ArticlePubMedGoogle Scholar
- le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007, 26: 3699-3708. 10.1038/sj.emboj.7601790PubMed CentralView ArticlePubMedGoogle Scholar
- Sutterlüty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, Krek W: p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999, 1: 207-214. 10.1038/12027View ArticlePubMedGoogle Scholar
- Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI: Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004, 6: 1229-1235. 10.1038/ncb1194View ArticlePubMedGoogle Scholar
- Ishida N, Kitagawa M, Hatakeyama S, Nakayama K: Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem. 2000, 275: 25146-25154. 10.1074/jbc.M001144200View ArticlePubMedGoogle Scholar
- Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S: p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001, 20: 6672-6682. 10.1093/emboj/20.23.6672PubMed CentralView ArticlePubMedGoogle Scholar
- Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM: A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006, 20: 47-64. 10.1101/gad.1384406PubMed CentralView ArticlePubMedGoogle Scholar
- Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI: Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem. 2002, 277: 14355-14358. 10.1074/jbc.C100762200View ArticlePubMedGoogle Scholar
- Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999, 13: 1181-1189. 10.1101/gad.13.9.1181PubMed CentralView ArticlePubMedGoogle Scholar
- Kossatz U, Vervoorts J, Nickeleit I, Sundberg HA, Arthur JS, Manns MP, Malek NP: C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J. 2006, 25: 5159-5170. 10.1038/sj.emboj.7601388PubMed CentralView ArticlePubMedGoogle Scholar
- Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ: Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA. 2006, 103: 15558-15563. 10.1073/pnas.0603877103PubMed CentralView ArticlePubMedGoogle Scholar
- Georgitsi M, Raitila A, Karhu A, Luijt van der RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA: CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. Clin Endocrinol Metab. 2007, 92: 3321-3325. 10.1210/jc.2006-2843.View ArticleGoogle Scholar
- Agarwal SK, Mateo CM, Marx SJ: Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in MEN1 and Related States. J Clin Endocrinol Metab. 2009, 94: 1826-1834. 10.1210/jc.2008-2083PubMed CentralView ArticlePubMedGoogle Scholar
- Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, Burman P, Wass JA, Quinton R, Grossman AB, Korbonits M: Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol. 2009, 70: 259-264. 10.1111/j.1365-2265.2008.03379.x.View ArticleGoogle Scholar
- Owens M, Stals K, Ellard S, Vaidya B: Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin Endocrinol. 2009, 70: 499-500. 10.1111/j.1365-2265.2008.03363.x.View ArticleGoogle Scholar
- Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE: Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell. 2000, 5: 403-410. 10.1016/S1097-2765(00)80435-9View ArticlePubMedGoogle Scholar
- Sprague BL, McNally JG: FRAP analysis of binding: proper and fitting. Trends Cell Biol. 2005, 15: 84-91. 10.1016/j.tcb.2004.12.001View ArticlePubMedGoogle Scholar
- Yang H, Zonder JA, Dou QP: Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009, 18: 957-971. 10.1517/13543780903002074PubMed CentralView ArticlePubMedGoogle Scholar
- Gillies JK, Lorimer IA: Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle. 2007, 6: 2005-2009. 10.4161/cc.6.16.4526View ArticlePubMedGoogle Scholar
- Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM: A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001, 413: 323-327. 10.1038/35095083View ArticlePubMedGoogle Scholar
- Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997, 3: 231-234. 10.1038/nm0297-231View ArticlePubMedGoogle Scholar
- Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001, 98: 5043-5048. 10.1073/pnas.081474898PubMed CentralView ArticlePubMedGoogle Scholar
- Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sörensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gütgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, Malek NP: Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell. 2008, 14: 23-35. 10.1016/j.ccr.2008.05.016View ArticlePubMedGoogle Scholar
- Sha MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004, 10: 6111-6118. 10.1158/1078-0432.CCR-04-0422View ArticleGoogle Scholar
- Fero ML, Rivkin M, Tasch M, Porter P, Carow CW, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996, 85: 733-744. 10.1016/S0092-8674(00)81239-8View ArticlePubMedGoogle Scholar
- Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996, 85: 707-720. 10.1016/S0092-8674(00)81237-4View ArticlePubMedGoogle Scholar
- Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996, 85: 721-732. 10.1016/S0092-8674(00)81238-6View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.